Tempus, A Leader In Artificial Intelligence And Precision Medicine, Today Announced A New Collaboration To Develop A Companion Diagnostic (Cdx) Test With Kartos Therapeutics, A Clinical Stage Biopharmaceutical Company, In Support Of Its Ongoing Phase Ii Study Of Navtemadlin (Krt-232). Tempus
